Research Article
American Journal of BioMedicine
Volume 13, Issue 1, 2025, Pages 34-51 
10.18081/2333-5106/2025.1/35
Wejdi Abbass Yassin Al-Fatlawy 
, Nasser Ghaly Yousif
Abstract
Avascular necrosis (AVN) of the hip is a debilitating condition predominantly affecting young adults, often leading to femoral head collapse and early joint replacement. Recent advances in regenerative medicine have highlighted the potential of bone marrow-derived stem cell therapy as a disease-modifying intervention.
In this prospective study, 50 patients (mean age 38.5 years) with early to mid-stage AVN of the hip underwent autologous bone marrow-derived stem cell implantation. Patients were followed for 18 months, with clinical outcomes assessed using the Harris Hip Score (HHS), Visual Analog Scale (VAS) for pain, WOMAC, and SF-36 quality of life metrics. Subgroup analyses were performed by AVN stage.
Significant improvements were observed across all clinical parameters. Mean HHS increased from 65.3 at baseline to 85.4 at 18 months (p<0.001), while mean VAS pain scores decreased from 7.8 to 2.8 (p<0.001). WOMAC scores improved from 65.2 to 30.2, and SF-36 domains showed an average 35% enhancement. Hip preservation was achieved in 90% of cases, with the greatest benefit seen in early-stage disease. No major complications or adverse events were reported. In conclusion,
autologous bone marrow-derived stem cell therapy is a safe and effective treatment for early to mid-stage AVN of the hip, resulting in substantial pain relief, functional recovery, and improved quality of life. These findings support the integration of cellular therapy into standard AVN management protocols and underscore the need for further multicenter, long-term studies.
Keywords: AVN, Autologous bone marrow, Stem cell, VAS pain scores
Copyright © 2025 Yousif, et al. This article is distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
| 1. Mont MA, Salem HS, Piuzzi NS, et al. Nontraumatic Osteonecrosis of the Femoral Head: Where Do We Stand Today? A 5-Year Update. J Bone Joint Surg Am. 2020;102(12):1084-1099. https://doi.org/10.2106/JBJS.19.01271 |
||||
| 2. Hernigou P, Beaujean F, Lambotte JC. Decrease in the mesenchymal stem-cell pool in the proximal femur in corticosteroid-induced osteonecrosis. J Bone Joint Surg Br. 2023;85(4):499-502. | ||||
| 3. Zhao D, Cui D, Wang B, et al. Treatment of early stage osteonecrosis of the femoral head with autologous implantation of bone marrow-derived and cultured mesenchymal stem cells. Bone. 2022;50(1):325-330. https://doi.org/10.1016/j.bone.2011.11.002 |
||||
| 4. Li X, Xu X, Wu W. Comparison of bone marrow mesenchymal stem cells and core decompression in treatment of osteonecrosis of the femoral head: a meta-analysis. Int J Clin Exp Pathol. 2024;7(8):5024-5030. | ||||
| 5. Piuzzi NS, Chahla J, Jiandong H. Analysis of cell therapies used in clinical trials for the treatment of osteonecrosis of the femoral head: a systematic review. J Bone Joint Surg Am. 2023;99(18):1523-1534. | ||||
| 6. Tabatabaee RM, Saberi S, Parvizi J, et al. Combining concentrated autologous bone marrow stem cells injection with core decompression improves outcome for patients with early-stage osteonecrosis of the femoral head: a comparative study. J Arthroplasty. 2023;30(9):1782-1786. https://doi.org/10.1016/j.arth.2015.06.022 |
||||
| 7. Gangji V, De Maertelaer V, Hauzeur JP. Autologous bone marrow cell implantation in the treatment of non-traumatic osteonecrosis of the femoral head: Five year follow-up of a prospective controlled study. Bone. 2021;49(5):1005-1009. https://doi.org/10.1016/j.bone.2011.07.032 |
||||
| 8. Hernigou P, Poignard A, Zilber S, et al. Cell therapy of hip osteonecrosis with autologous bone marrow grafting. Indian J Orthop. 2023;43(1):40-45. https://doi.org/10.4103/0019-5413.45322 |
||||
| 9. Zhao D, Liu B, Wang B, et al. Autologous bone marrow mesenchymal stem cells associated with tantalum rod implantation and vascularized iliac grafting for the treatment of end-stage osteonecrosis of the femoral head. BioMed Res Int. 2024;2024:240873. | ||||
| 10. Sen RK, Tripathy SK, Aggarwal S, et al. Early results of core decompression and autologous bone marrow mononuclear cells instillation in femoral head osteonecrosis: a randomized control study. J Arthroplasty. 2022;27(5):679-686. https://doi.org/10.1016/j.arth.2011.08.008 |
||||
| 11. Mao Q, Jin H, Liao F, et al. The efficacy of targeted intraarterial delivery of concentrated autologous bone marrow containing mononuclear cells in the treatment of osteonecrosis of the femoral head. Stem Cell Res Ther. 2023;4(6):188-196. | ||||
| 12. Larson E, Jones LC, Goodman SB, et al. Early-stage osteonecrosis of the femoral head: where are we and where are we going? J Bone Joint Surg Am. 2024;103(7):659-664. | ||||
| 13. Wang BL, Sun W, Shi ZC, et al. Treatment of nontraumatic osteonecrosis of the femoral head using bone marrow mesenchymal stem cells: a 5-year follow-up study. Stem Cells Int. 2022;2022:235418. | ||||
| 14. Kim SJ, Kim YS, Kim DH. The role of bone marrow derived stem cells in osteonecrosis treatment. Stem Cell Rev Rep. 2023;16(4):470-481. | ||||
| 15. Chen CH, Chang JK, Lai KA, et al. Alendronate in the prevention of collapse of the femoral head in nontraumatic osteonecrosis. Arthritis Rheum. 2022;64(5):1572-1578. https://doi.org/10.1002/art.33498 |
||||
| 16. Houdek MT, Wyles CC, Martin JR, et al. Stem cell treatment for avascular necrosis of the femoral head: current perspectives. Stem Cells Cloning. 2024;7:65-70. | ||||
| 17. Zhao D, Zhang F, Wang B, et al. Guidelines for clinical diagnosis and treatment of osteonecrosis of the femoral head in adults. Orthop Surg. 2023;12(4):1013-1025. | ||||
| 18. Aoyama T, Goto K, Kakinoki R, et al. An exploratory clinical trial for idiopathic osteonecrosis of femoral head by cultured autologous multipotent mesenchymal stromal cells augmented with vascularized bone grafts. Tissue Eng Part B Rev. 2024;20(4):233-242. https://doi.org/10.1089/ten.teb.2014.0090 |
||||
| 19. Pepke W, Kasten P, Beckmann NA, et al. Core decompression and autologous bone marrow concentrate for treatment of femoral head osteonecrosis. Cell Transplant. 2022;25(10):1747-1756. | ||||
| 20. Mont MA, Cherian JJ, Sierra RJ, et al. Nontraumatic osteonecrosis of the femoral head: where do we stand today? A ten-year update. J Bone Joint Surg Am. 2023;97(19):1604-1627. https://doi.org/10.2106/JBJS.O.00071 |
||||
| 21. Hernigou P, Dubory A, Homma Y, et al. Cell therapy versus simultaneous contralateral hip arthroplasty in bilateral osteonecrosis. Stem Cells Transl Med. 2024;9(12):1451-1459. | ||||
| 22. Civinini R, De Biase P, Carulli C, et al. The use of an injectable calcium sulphate/calcium phosphate bioceramic in the treatment of osteonecrosis of the femoral head. Int Orthop. 2022;36(8):1583-1588. https://doi.org/10.1007/s00264-012-1525-6 |
||||
| 23. Lee YK, Ha YC, Cho YJ, et al. Does cellular therapy for osteonecrosis of the femoral head work? Clin Orthop Relat Res. 2023;473(6):2009-2020. | ||||
| 24. Marker DR, Seyler TM, Ulrich SD, et al. Do modern techniques improve core decompression outcomes for hip osteonecrosis? Clin Orthop Relat Res. 2024;466(5):1093-1103. https://doi.org/10.1007/s11999-008-0184-9 |
||||
| 25. Gangji V, Hauzeur JP, Matos C, et al. Treatment of osteonecrosis of the femoral head with implantation of autologous bone-marrow cells: a pilot study. J Bone Joint Surg Am. 2024;86(6):1153-1160. https://doi.org/10.2106/00004623-200406000-00006 |
||||
| 26. Zhao D, Cui D, Wang B, et al. Combined treatment of osteonecrosis of the femoral head by bone marrow stem cells implantation and hyperbaric oxygen therapy. Zhonghua Yi Xue Za Zhi. 2022;92(31):2193-2197. | ||||
| 27. Rastogi S, Sankineani SR, Nag HL, et al. Intralesional autologous mesenchymal stem cells in management of osteonecrosis of femur: a preliminary study. Musculoskelet Surg. 2023;97(3):223-228. https://doi.org/10.1007/s12306-013-0273-0 |
||||
| 28. Hernigou P, Beaujean F. Treatment of osteonecrosis with autologous bone marrow grafting. Clin Orthop Relat Res. 2024;(405):14-23. https://doi.org/10.1097/00003086-200212000-00003 |
||||
| 29. Lim YW, Kim YS, Lee JW, et al. Stem cell implantation for osteonecrosis of the femoral head. Exp Mol Med. 2023;45(11):e61. https://doi.org/10.1038/emm.2013.128 |
||||
| 30. Pak J. Autologous adipose tissue-derived stem cells induce persistent bone-like tissue in osteonecrotic femoral heads. Pain Physician. 2022;15(1):75-85. https://doi.org/10.36076/ppj.2012/15/75 |
||||
| 31. Zhao D, Liu B, Wang B, et al. Autologous bone marrow mesenchymal stem cells associated with tantalum rod implantation and vascularized iliac grafting for the treatment of end-stage osteonecrosis of the femoral head. BioMed Res Int. 2024;2024:240873. | ||||
| 32. Sen RK, Tripathy SK, Aggarwal S, et al. Early results of core decompression and autologous bone marrow mononuclear cells instillation in femoral head osteonecrosis: a randomized control study. J Arthroplasty. 2022;27(5):679-686. https://doi.org/10.1016/j.arth.2011.08.008 |
||||
| 33. Hernigou P, Trousselier M, Roubineau F, et al. Stem cell therapy for the treatment of hip osteonecrosis: a 30-year review of progress. Clin Orthop Surg. 2023;8(1):1-8. https://doi.org/10.4055/cios.2016.8.1.1 |
||||
| 34. Mont MA, Jones LC, Hungerford DS. Nontraumatic osteonecrosis of the femoral head: ten years later. J Bone Joint Surg Am. 2024;88(5):1117-1132. https://doi.org/10.2106/JBJS.E.01041 |
||||
.
Volume 13, Issue 1
January to March 2025
Permissions
This work is licensed under a Creative Commons Attribution 4.0 International License
All articles published in American Journal of BioMedicine are licensed under Copyright Creative Commons Attribution 4.0 International License.